Oncolytic plasmid: A novel strategy for tumor immuno-gene therapy

Yoshihara,Chieko; Hamada,Katsuyuki; Kuroda,Minako; Koyama,Yoshiyuki

doi:10.3892/ol.2011.467

Oncolytic plasmid: A novel strategy for tumor immuno-gene therapy

Authors:
- Chieko Yoshihara
- Katsuyuki Hamada
- Minako Kuroda
- Yoshiyuki Koyama
View Affiliations

Affiliations: Department of Textile Science, Otsuma Women's University, Tokyo 102-8357, Japan, Department of Obstetrics and Gynecology, School of Medicine, Ehime University, Ehime 791-0295, Japan
Published online on: October 31, 2011 https://doi.org/10.3892/ol.2011.467
Pages: 387-390

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The oncolytic virus is expected to proliferate in and destroy tumor cells. The virus is also thought to generate antitumor immunity. Virally infected tumor cells express viral antigens on their surfaces. Such tumor cells or their fragments would be taken up by antigen-presenting cells (APCs) together with tumor-associated antigens (TAAs), and facilitated cross‑priming of tumor-specific T cells. Virus-specific protein presented on the infected cells therefore played a crucial role in the enhancement of the adaptive antitumor immunity. In this study, a plasmid encoding adenovirus protein, the adenovirus death protein (ADP), was constructed, and a very fine complex of the plasmid with polyethylenimine (PEI) and chondroitin sulfate (CS) was injected into tumor-bearing mice. Transfection of the ADP gene was shown to suppress tumor growth as effectively as granulocyte-macrophage colony-stimulating factor (GM-CSF) transfection. When mice were administered plasmid coding ADP (pDNA‑ADP) to generate an immune response to ADP prior to therapy, transfection of the ADP gene induced a much higher level of tumor growth suppression than that found in the non-immunized mice. An evident synergistic effect of ADP and GM-CSF genes was also observed, and at a pDNA-ADP/pDNA-GM-CSF ratio of 4:1, significant suppression of tumor growth was achieved even in the non-immunized mice.

View Figures

View References

1	De Pace NG: Sulla scomparsa di un enorme cancro vegetante del collo dell’utero senza cura chirurgica. Ginecologia. 9:82–88. 1912.
2	Martuza RL, Malick A, Markert JM, Ruffner KL and Coen DM: Experimental therapy of human glioma by means of a mutant. Science. 252:854–856. 1991. View Article : Google Scholar : PubMed/NCBI
3	Todo T, Rabkin SD, Sundaresan P, Wu A, Meehan KR, Herscowitz HB and Martuza RL: Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther. 10:2741–2755. 1999. View Article : Google Scholar
4	Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA and Errington F: Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther. 8:1581–1588. 2008. View Article : Google Scholar : PubMed/NCBI
5	Suzuki K, Alemany R, Yamamoto M and Curiel DT: The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res. 8:3348–3359. 2002.PubMed/NCBI
6	Wold WSM, Cladaras C, Magie SC and Yacoub N: Mapping a new gene that encodes an 11,600-molecular-weight protein in the E3 transcription unit of adenovirus 2. J Virol. 52:307–313. 1984.PubMed/NCBI
7	Tollefson AE, Ryerse JS, Scaria A, Hermiston TW and Wold WS: The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Virology. 220:152–162. 1996. View Article : Google Scholar : PubMed/NCBI
8	Wold WSM, Doronin K, Toth K, Kuppuswamy M, Lichtenstein DL and Tollefson AE: Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr Opin Immunol. 11:380–386. 1999. View Article : Google Scholar : PubMed/NCBI
9	Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ and Wold WS: The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol. 70:2296–2306. 1996.PubMed/NCBI
10	Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE and Wold WS: Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol. 74:6147–6155. 2000. View Article : Google Scholar : PubMed/NCBI
11	Ito T, Yoshihara C, Hamada K and Koyama Y: DNA/polyethyl eneimine/hyaluronic acid small complex particles and tumor suppression in mice. Biomaterials. 31:2912–2918. 2010. View Article : Google Scholar : PubMed/NCBI
12	Lavoie JN, Nguyen M, Marcellus RC, Branton PE and Shore GC: E4orf4, a novel adenovirus death factor that induces p53-independent apoptosis by a pathway that is not inhibited by zVADfmk. J Cell Biol. 140:637–645. 1998. View Article : Google Scholar : PubMed/NCBI
13	Malhotra S, Kim T, Zager J, Bennett J, Ebright M, D’Angelica M and Fong Y: Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas. Surgery. 141:520–529. 2007. View Article : Google Scholar : PubMed/NCBI
14	Hamada K, Desaki J, Nakagawa K, Zhang T, Shirakawa T, Gotoh A and Tagawa M: Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy. Mol Ther. 15:1121–1128. 2007.PubMed/NCBI
15	Todo T, Rabkin SD, Sundaresan P, Wu A, Meehan KR, Herscowitz HB and Martuza RL: Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther. 10:2741–2755. 1999. View Article : Google Scholar
16	Weber LW, Bowne WB, Wolchok JD, Srinivasan R, Qin J, Moroi Y, Clynes R, Song P, Lewis JJ and Houghton AN: Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Investig. 102:1258–1264. 1998. View Article : Google Scholar : PubMed/NCBI
17	Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, Wulderk M, Jeffers Y, Sadelain M, Hohenhaus AE, Segal N, Gregor P, Engelhorn M, Riviere I, Houghton AN and Wolchok JD: Clin Cancer Res. 9:1284–1290. 2003.
18	Tang DC, DeVit M and Johnston SA: Genetic immunization is a simple method for eliciting an immune response. Nature. 356:152–154. 1992. View Article : Google Scholar : PubMed/NCBI